178 related articles for article (PubMed ID: 37949350)
1. Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities.
Lenoci D; Resteghini C; Serafini MS; Pistore F; Canevari S; Ma B; Cavalieri S; Alfieri S; Trama A; Licitra L; De Cecco L
Transl Res; 2024 Mar; 265():1-16. PubMed ID: 37949350
[TBL] [Abstract][Full Text] [Related]
2. Multiplex Epstein-Barr virus BALF2 genotyping detects high-risk variants in plasma for population screening of nasopharyngeal carcinoma.
Miller JA; Sahoo MK; Yamamoto F; Huang C; Wang H; Zehnder JL; Le QT; Pinsky BA
Mol Cancer; 2022 Jul; 21(1):154. PubMed ID: 35902864
[TBL] [Abstract][Full Text] [Related]
3. Natural Variations in BRLF1 Promoter Contribute to the Elevated Reactivation Level of Epstein-Barr Virus in Endemic Areas of Nasopharyngeal Carcinoma.
Zhang JB; Huang SY; Wang TM; Dong SQ; He YQ; Zheng XH; Li XZ; Wang F; Jianbing M; Jia WH
EBioMedicine; 2018 Nov; 37():101-109. PubMed ID: 30420297
[TBL] [Abstract][Full Text] [Related]
4. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
[TBL] [Abstract][Full Text] [Related]
5. BART-D2 subtype of EBV encoded BART miRNA cluster 1 region is strongly associated with endemic nasopharyngeal carcinoma.
Wang Q; He H; Ji X; Liu Y; Li H; Wang Y
J Med Virol; 2023 Mar; 95(3):e28667. PubMed ID: 36912378
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
[TBL] [Abstract][Full Text] [Related]
7. Enhancer infestation drives tumorigenic activation of inactive B compartment in Epstein-Barr virus-positive nasopharyngeal carcinoma.
Mizokami H; Okabe A; Choudhary R; Mima M; Saeda K; Fukuyo M; Rahmutulla B; Seki M; Goh BC; Kondo S; Dochi H; Moriyama-Kita M; Misawa K; Hanazawa T; Tan P; Yoshizaki T; Fullwood MJ; Kaneda A
EBioMedicine; 2024 Apr; 102():105057. PubMed ID: 38490101
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr viral product-containing exosomes promote fibrosis and nasopharyngeal carcinoma progression through activation of YAP1/FAPα signaling in fibroblasts.
Lee PJ; Sui YH; Liu TT; Tsang NM; Huang CH; Lin TY; Chang KP; Liu SC
J Exp Clin Cancer Res; 2022 Aug; 41(1):254. PubMed ID: 35986369
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus DNA seropositivity links distinct tumoral heterogeneity and immune landscape in nasopharyngeal carcinoma.
Li W; Lv S; Liu G; Lu N; Jiang Y; Liang H; Xia W; Xiang Y; Xie C; He J
Front Immunol; 2023; 14():1124066. PubMed ID: 36860875
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
Guo J; Cui Z; Zheng Y; Li X; Chen Y
Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
[TBL] [Abstract][Full Text] [Related]
11. The influence of human papillomavirus on nasopharyngeal carcinoma in Japan.
Kano M; Kondo S; Wakisaka N; Moriyama-Kita M; Nakanishi Y; Endo K; Murono S; Nakamura H; Yoshizaki T
Auris Nasus Larynx; 2017 Jun; 44(3):327-332. PubMed ID: 27499435
[TBL] [Abstract][Full Text] [Related]
12. Tumor residue in patients with stage II-IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein-Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose.
Huang YY; Zhou JY; Zhan ZJ; Ke LR; Xia WX; Cao X; Cai ZC; Deng Y; Chen X; Zhang LL; Huang HY; Guo X; Lv X
BMC Cancer; 2023 May; 23(1):410. PubMed ID: 37149594
[TBL] [Abstract][Full Text] [Related]
13. Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study.
Chen QY; Guo SY; Tang LQ; Lu TY; Chen BL; Zhong QY; Zou MS; Tang QN; Chen WH; Guo SS; Liu LT; Li Y; Guo L; Mo HY; Sun R; Luo DH; Zhao C; Cao KJ; Qian CN; Guo X; Zeng MS; Mai HQ
Cancer Res Treat; 2018 Jul; 50(3):861-871. PubMed ID: 28903550
[TBL] [Abstract][Full Text] [Related]
14. Updates on Epstein-Barr Virus (EBV)-Associated Nasopharyngeal Carcinoma: Emphasis on the Latent Gene Products of EBV.
Ahmed N; Abusalah MAHA; Farzand A; Absar M; Yusof NY; Rabaan AA; AlSaihati H; Alshengeti A; Alwarthan S; Alsuwailem HS; Alrumaih ZA; Alsayyah A; Yean CY
Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676626
[TBL] [Abstract][Full Text] [Related]
15. Nasopharyngeal Carcinoma Progression: Accumulating Genomic Instability and Persistent Epstein-Barr Virus Infection.
Liu X; Deng Y; Huang Y; Ye J; Xie S; He Q; Chen Y; Lin Y; Liang R; Wei J; Li Y; Zhang J
Curr Oncol; 2022 Aug; 29(9):6035-6052. PubMed ID: 36135044
[TBL] [Abstract][Full Text] [Related]
16. Establishment and Characterization of an Epstein-Barr Virus-positive Cell Line from a Non-keratinizing Differentiated Primary Nasopharyngeal Carcinoma.
Chai AWY; Yee SM; Lee HM; Abdul Aziz N; Yee PS; Marzuki M; Wong KW; Chiang AKS; Chow LK; Dai W; Liu TF; Tan LP; Khoo ASB; Lo KW; Lim PVH; Rajadurai P; Lightfoot H; Barthorpe S; Garnett MJ; Cheong SC
Cancer Res Commun; 2024 Mar; 4(3):645-659. PubMed ID: 38358347
[TBL] [Abstract][Full Text] [Related]
17. Epigenomic landscape study reveals molecular subtypes and EBV-associated regulatory epigenome reprogramming in nasopharyngeal carcinoma.
Ka-Yue Chow L; Lai-Shun Chung D; Tao L; Chan KF; Tung SY; Cheong Ngan RK; Ng WT; Wing-Mui Lee A; Yau CC; Lai-Wan Kwong D; Ho-Fun Lee V; Lam KO; Liu J; Chen H; Dai W; Lung ML
EBioMedicine; 2022 Dec; 86():104357. PubMed ID: 36371985
[TBL] [Abstract][Full Text] [Related]
18. Genomic landscape of Epstein-Barr virus in familial nasopharyngeal carcinoma.
Zhang WL; Zhang JB; Wang TM; Wu YX; He YQ; Xue WQ; Liao Y; Deng CM; Li DH; Wu ZY; Yang DW; Zheng XH; Li XZ; Zhou T; Zhang PF; Zhang SD; Hu YZ; Jia WH
J Gen Virol; 2022 Mar; 103(3):. PubMed ID: 35349400
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
Fung SY; Lam JW; Chan KC
Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
[TBL] [Abstract][Full Text] [Related]
20. EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma.
Lung RW; Hau PM; Yu KH; Yip KY; Tong JH; Chak WP; Chan AW; Lam KH; Lo AK; Tin EK; Chau SL; Pang JC; Kwan JS; Busson P; Young LS; Yap LF; Tsao SW; To KF; Lo KW
J Pathol; 2018 Apr; 244(4):394-407. PubMed ID: 29230817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
